© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
MPNs
JAK Inhibition Shakes Up MPN Paradigm With 2 Potential Additions to the Armamentarium
September 10, 2020
JAK inhibitors continue to make a splash in the treatment landscape of MPNs and are be evaluated in multiple clinical trials, and the advancement of these agents should be recognized in honor of MPN Awareness Day.
Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms
September 07, 2020
Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.
Novel Targets Outside of JAK Inhibition Inching into Myelofibrosis Treatment Landscape
August 31, 2020
Experts in myeloproliferative neoplasms find janus kinase inhibitors to be particularly important to the armamentarium for the treatment of myelofibrosis. With only 2 FDA-approved agents, fedratinib and ruxolitinib, and the inevitability that not all patients will derive benefit, and some will develop resistance, the option of moving beyond JAK inhibition is widely discussed.
Targeted Therapy Combinations With JAK inhibition Show Early Promise for Myelofibrosis
August 31, 2020
Patients with myelofibrosis have complicated pathology and multiple pathways, creating the opportunity to use multiple targeted agents for treatment, but also leading to greater potential for resistance to monotherapy, according to Lucia Masarova, MD.
Targeted Approach Considered for the Treatment of Accelerated/Blast Phase MPNs
August 31, 2020
Standard treatment for accelerated or blast phase myeloproliferative neoplasms consists of hypomethylating agents or intensive induction chemotherapy and transplant. However, newer studies have suggested that accelerated or blast phase MPNs, such as acute myeloid leukemia, can be treated with molecularly driven targeted therapies.
JAK Inhibitors Enter Treatment Landscape for Patients With Early Myelofibrosis
August 28, 2020
In an interview with Targeted Oncology, Ruben Mesa, director, MD, discussed the role of JAK inhibitors in early myelofibrosis and other promising treatment options coming down the pipeline.
The Possibilities and Limitations of Ruxolitinib in the Modern MPNs Paradigm
August 28, 2020
During the 1st Annual Texas MPM Workshop, Aaron Gerds, MD, MS presented on the ruxolitinib in the present and future, as well as the possibilities for moving beyond the JAK-STAT pathway.
Determining Who Has “Early Myelofibrosis” Involves a Broad Look at Patient Factors
August 28, 2020
Patients considered to have early myelofibrosis are a heterogeneous group for whom disease risk, best treatment strategies, and the probability of mortality are best determined individually by looking at patient’s clinical characteristics and molecular markers together.
CPI-0610 Shows Clinical Activity in Patients With Myelofibrosis
August 13, 2020
Srdan Verstovsek, MD, PhD, discusses the data seen in the phase 2 trial of CPI-0610 with or without ruxolitinib in patients with myelofibrosis.
Mesa Discusses Treating Myelofibrosis and Other MPNs
August 07, 2020
Ruben Mesa, MD, reviewed a case of a 68-year-old woman with a myeloproliferative neoplasm, during a virtual Case Based Peer Perspectives event.